Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.
Beltrán-Visiedo M, Jiménez-Alduán N, Díez R, Cuenca M, Benedi A, Serrano-Del Valle A, Azaceta G, Palomera L, Peperzak V, Anel A, Naval J, Marzo I. Beltrán-Visiedo M, et al. Among authors: diez r. Mol Oncol. 2023 Dec;17(12):2507-2525. doi: 10.1002/1878-0261.13522. Epub 2023 Sep 28. Mol Oncol. 2023. PMID: 37704591 Free PMC article.
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.
Serrano Del Valle A, Beltrán-Visiedo M, de Poo-Rodríguez V, Jiménez-Alduán N, Azaceta G, Díez R, Martínez-Lázaro B, Izquierdo I, Palomera L, Naval J, Anel A, Marzo I. Serrano Del Valle A, et al. Among authors: diez r. Oncoimmunology. 2022 Nov 1;11(1):2141973. doi: 10.1080/2162402X.2022.2141973. eCollection 2022. Oncoimmunology. 2022. PMID: 36338146 Free PMC article.
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I, Villamón E, Abellán R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutiérrez M, Collado R, García-Serra R, Vara M, Blanco ML, Oiartzabal I, Álvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil Á, Díez-Campelo M, Solano C, Tormo M; Spanish Group of Myelodysplastic Syndromes (GESMD). Martín I, et al. Among authors: diez r. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. Br J Haematol. 2021. PMID: 34296432
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, Présumey J, Hernandez J, Cartron G, Giraldos D, Díez R, Izquierdo I, Azaceta G, Palomera L, Marzo I, Naval J, Anel A, Villalba M. Reina-Ortiz C, et al. Among authors: diez r. Oncoimmunology. 2020 Dec 29;10(1):1853314. doi: 10.1080/2162402X.2020.1853314. Oncoimmunology. 2020. PMID: 33457074 Free PMC article.
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes-Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group. Pardal E, et al. Among authors: diez r. Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 May 6. Am J Hematol. 2018. PMID: 29658143 Free article.
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Vilorio-Marqués L, Castañón Fernández C, Mora E, Gutiérrez L, Rey Bua B, Jiménez Lorenzo MJ, Díaz Beya M, Vara Pampliega M, Molero A, Sánchez-García J, Calabuig M, Cedena MT, Chen-Liang T, Díaz Santa JA, Padilla I, Hernández F, Díez R, Asensi P, Xicoy B, Sanz G, Valcárcel D, Diez-Campelo M, Bernal T. Vilorio-Marqués L, et al. Among authors: diez r. Ther Adv Hematol. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36199837 Free PMC article.